Cargando…
Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy
The purpose of this study was to investigate the effects of SLC22A2 808G>T polymorphism and trough concentrations (C(0)) of bosutinib on serum creatinine in 28 patients taking bosutinib. At 1, 3, 6, 12, 24, and 36 months after administration, analysis of bosutinib C(0) and creatinine was performe...
Autores principales: | Abumiya, Maiko, Takahashi, Naoto, Takahashi, Saori, Yoshioka, Tomoko, Kameoka, Yoshihiro, Miura, Masatomo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973796/ https://www.ncbi.nlm.nih.gov/pubmed/33737618 http://dx.doi.org/10.1038/s41598-021-85757-7 |
Ejemplares similares
-
Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia
por: Mita, Akiko, et al.
Publicado: (2018) -
Bosutinib for Chronic Myeloid Leukemia
por: Breccia, Massimo, et al.
Publicado: (2015) -
Bosutinib in chronic myeloid leukemia: patient selection and perspectives
por: Isfort, Susanne, et al.
Publicado: (2018) -
Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain
por: Levinson, Nicholas M., et al.
Publicado: (2012) -
Bosutinib in the management of chronic myelogenous leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)